Skip to content
Biophytis
LIVE HEALTHIER LONGER
Corporate
Executive Committee
Scientific Advisory Board
Boards of Directors
Code of Ethics
Our Science
BIO101
Posters & Publications
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Macuneos (BIO201)
Posters & Publications
Pipeline
Pipeline
Key milestones in the development of BIO101
Sarcopenia: SARA clinical program
Obesity: OBA Clinical Program
COVID-19: COVA clinical program
Duchenne Muscular Dystrophy: MYODA clinical program
Age-related Macular Degeneration: MACA clinical program
Investors
Live Stock Price
Corporate Presentation
General Meetings
2024
2023
2022
2021
2020
AMF Regulated Information
SEC Filings
Financial Calendar
Convertible bonds
News
Press Releases
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Biophytis in Media
Recruitment
Contact
Contact
Contact Information
Legal information
LinkedIn
Twitter
EN
Corporate
Executive Committee
Scientific Advisory Board
Boards of Directors
Code of Ethics
Our Science
BIO101
Posters & Publications
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Macuneos (BIO201)
Posters & Publications
Pipeline
Pipeline
Key milestones in the development of BIO101
Sarcopenia: SARA clinical program
Obesity: OBA Clinical Program
COVID-19: COVA clinical program
Duchenne Muscular Dystrophy: MYODA clinical program
Age-related Macular Degeneration: MACA clinical program
Investors
Live Stock Price
Corporate Presentation
General Meetings
2024
2023
2022
2021
2020
AMF Regulated Information
SEC Filings
Financial Calendar
Convertible bonds
News
Press Releases
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Biophytis in Media
Recruitment
Contact
Contact
Contact Information
Legal information
LinkedIn
Twitter
EN
Key milestones in the development of BIO101
Go to Top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok
